Clinical Trial

Force Control in Chronic Obstructive Pulmonary Disease

Study acronym: NEUROTIGUE F
Completed
View on ClinicalTrials.gov →
Summary
Maximal muscle strength is one of the most commonly assessed neuromuscular parameters in people with COPD due to its accessibility and relevance for prescribing an appropriate workload for resistance training. However, maximal force production is very rarely necessary during daily activities which requires production of submaximal and precisely controlled forces. Despite growing research on motor impairments in COPD, very little attention has been given to the effect of this disease on force control. Therefore, this research aims to better understand the potential deficits in force control caused by COPD, through the use of advanced signal processing methods (i.e., nonlinear approaches). We hypothesized that force control would be reduced in people with COPD compared to healthy individuals, particularly at low force levels.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-03-11; most recent amendment 2026-07-06.
Status change: Recruiting → Completed 2025-08-05
Trial Details
NCT Number NCT06871670
Lead Sponsor Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborators: Université de Toulon
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 36 participants
Start Date 2025-03-07
Primary Completion 2025-03-08 (estimated)
Study Completion 2025-03-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-07